Opthea Ltd has released a press release.
Opthea Ph2b Trial Results with OPT-302 published in Journal
Filed with ASX ·
6ix hasn’t read this filing yet.
Story so far
Earlier from Opthea
- Opthea Corporate Presentation - San Francisco Jan 2023
- Chairmans Address to Shareholders
- Completion of Share Purchase Plan
- Opthea reports Fiscal Year 2022 Results and Highlights
- Opthea Appendix 4E and Annual Report 2022
Later from Opthea
- Response to ASX Query
- Half Year Accounts
- Opthea Receives A$8.7million R&D Tax Incentive
- ASRS 2023 - PK and safety of sozinibercept (OPT-302)
- Opthea announces A$80m Capital raise
Follow Opthea into a list and get an email when it puts out news.
Follow Opthea